March 2, 2016

Biohit’s Indian distribution deal easy to stomach

The agreement seeks to prevent people becoming patients by focusing on key disease areas contributing to death rates in India and bringing advanced technologies for early diagnosis.
The agreement seeks to prevent people becoming patients by focusing on key disease areas contributing to death rates in India and bringing advanced technologies for early diagnosis.
Istock.com/powerofforever

Finnish biotechnology company Biohit and Onsite Diagnostic Labs India (ODL) have signed a distributor agreement for Biohit’s diagnostic portfolio in India.

Biohit’s Celiac Quick test contributes to substantial savings in healthcare costs, by reducing the number of unnecessary endoscopies.

Biohit’s Celiac Quick test contributes to substantial savings in healthcare costs, by reducing the number of unnecessary endoscopies.

Biohit

ODL will solely focus on the marketing of Biohit tests across the subcontinent.

“Utilising the innovative tests from the Biohit portfolio, based on advanced technology, we are making early stomach health screening more accessible and affordable for Indians everywhere,” states Jagdeep Singh, ODL’s CEO.

The diagnostic tests covered by the distribution agreement include Gastro Panel, for identifying a range of stomach-related ailments; Active vitamin B12 test, which measures the blood levels of circulating active B12 vitamin; and Celiac Quick test, a diagnostic tool for identifying celiac disease.

Other Biohit products to become available in India include Calprotectin test, which differentiates inflammatory bowel disease (IBD) from irritable bowel syndrome (IBS) as well as in monitoring treatment in IBD patients; and Colon View-Fit, used in the screening of colorectal cancer.

Looking for more good news? Subscribe to our newsletter

Share: